Bacteraernia in febrile neutropenic cancer patients

被引:244
|
作者
Klastersky, J. [1 ]
Ameye, L. [1 ]
Maertens, J. [1 ]
Georgala, A. [1 ]
Muanza, F. [1 ]
Aoun, M. [1 ]
Ferrant, A. [1 ]
Rapoport, B. [1 ]
Rolston, K. [1 ]
Paesmans, M. [1 ]
机构
[1] Inst Jules Bordet, Data Ctr, B-1000 Brussels, Belgium
关键词
febrile neutropenia; bactererma; risk prediction;
D O I
10.1016/j.ijantimicag.2007.06.012
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A total of 2142 patients with febrile neutropenia resulting from cancer chemotherapy were registered in two observational studies and followed prospectively indifferent institutions. There were 499 (23%) patients with bacteraemia who are reviewed here. The relative frequencies of Gram-positive, Gram-negative and polymicrobial bacteraemias were 57%, 34% and 10% with respective mortality rates of 5%, 18% and 13%. Mortality rates were significantly higher in bacteraemic patients than in non-bacteraemic patients; a trend for higher mortality was observed (without reaching statistical significance) in those patients in whom bacteraemia was associated with a clinical site of infection compared to bacteraemic patients without any clinical documentation. Prophylactic antibiotics but not granulopoiesis stimulating factors were associated with a lower incidence of Gram-negative bacteraemia; however, neither prophylactic approach influenced the subsequent rate of complications in the patients who developed bacteraemia. The present study also confirms that the MASCC scoring system can identify a group of bacteraemic patients with a relatively low risk of complications and death (MASCC >= 21). On the other hand, in patients with very low levels of the MASCC score (<15), and then with predicted very unfavourable risk, the rate of complications and death was dramatically high, irrespective of the microbiological nature of the bacteraemia. (C) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:S51 / S59
页数:9
相关论文
共 50 条
  • [1] Blood cultures in febrile neutropenic patients with cancer
    Novin, K.
    Ameri, A.
    Yeganeh, S. H.
    Faghani, Y.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [2] OUTPATIENT TREATMENT OF FEBRILE NEUTROPENIC PATIENTS WITH CANCER
    RUBENSTEIN, EB
    ROLSTON, KVI
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A (01) : 2 - 4
  • [3] Lactobacillus bacteremia in febrile neutropenic patients in a cancer hospital
    Cooper, CD
    Vincent, A
    Greene, JN
    Sandin, RL
    Cobian, L
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (05) : 1247 - 1248
  • [4] MANAGEMENT OF FEBRILE EPISODES IN NEUTROPENIC CANCER-PATIENTS
    BISHOP, JF
    MCLENNAN, R
    WHITESIDE, MG
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1977, 1 (14) : 473 - 475
  • [5] CONTROVERSIES IN THE MANAGEMENT OF FEBRILE NEUTROPENIC CANCER-PATIENTS
    RUBIN, M
    HATHORN, JW
    PIZZO, PA
    [J]. CANCER INVESTIGATION, 1988, 6 (02) : 167 - 184
  • [6] EMPIRICAL ANTIBIOTICS FOR FEBRILE NEUTROPENIC CANCER-PATIENTS
    HATHORN, JW
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 : S43 - S51
  • [7] Carbapenems in febrile neutropenic patients
    Gaya, H
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (05) : 667 - 668
  • [8] Fluconazole versus amphotericin B in febrile neutropenic patients with cancer
    Allan R. Tunkel
    [J]. Current Infectious Disease Reports, 2000, 2 (5) : 389 - 390
  • [9] Outpatient oral antibiotics for febrile neutropenic cancer patients - Reply
    Paesmans, Marianne
    Klastersky, Jean
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (35) : 5614 - 5615
  • [10] Identifying neutropenic febrile cancer patients at risk for early death
    Wilbur, DW
    Rentschler, RE
    Couperus, JJ
    Camacho, ES
    Godfrey, TE
    Hilliard, DA
    [J]. INFECTIONS IN MEDICINE, 2000, 17 (05) : 347 - +